Use of statins in lower extremity artery disease: A review

BMC Surgery

Volumn 12, Issue SUPPL. 1, 2012, Pages

  Gargiulo, Giuseppe ^a   Giugliano, Giuseppe ^a   Brevetti, Linda ^a   Sannino, Anna ^a   Schiattarella, Gabriele Giacomo ^a   Serino, Federica ^a   Carbone, Andreina ^a   Scudiero, Fernando ^a   Ferrone, Marco ^a   Corrado, Roberto ^a   Izzo, Raffaele ^a   Chiariotti, Lorenzo ^a   Perrino, Cinzia ^a   Amato, Bruno ^a   Trimarco, Bruno ^a   Esposito, Giovanni ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

HUMAN; LEG; PERIPHERAL OCCLUSIVE ARTERY DISEASE; QUALITY OF LIFE; REVIEW; TREATMENT OUTCOME;

HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOWER EXTREMITY; PERIPHERAL ARTERIAL DISEASE; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 84869450123     PISSN: None     EISSN: 14712482     Source Type: Journal    
DOI: 10.1186/1471-2482-12-S1-S15     Document Type: Review

References (24)

1. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). Tendera M, Aboyans V, Bartelink ML, Baumgartner I, Clement D, Collet JP, Cremonesi A, De Carlo M, Erbel R, Fowkes FG, et al. Eur Heart J 2011 32 22 2851 2906 21873417
2. Giugliano, G., Di Serafino, L., Perrino, C., Schiano, V., Laurenzano, E., Cassese, S., De Laurentis, M., Schiattarella, G.G., Brevetti, L., Sannino, A., Gargiulo, G., Franzone, A., Indolfi, C., Piscione, F., Trimarco, B., Esposito, G., 2013, Effects of successful percutaneous lower extremity revascularization on cardiovascular outcome in patients with peripheral arterial disease, International Journal of Cardiology, 167(6), 2566-2571
3. Femoral plaque echogenicity and cardiovascular risk in claudicants. Schiano V, Sirico G, Giugliano G, Laurenzano E, Brevetti L, Perrino C, Brevetti G, Esposito G, JACC Cardiovasc Imaging 2012 5 4 348 357 10.1016/j.jcmg.2012.01. 011 22498323
4. Cardiovascular effects of treadmill exercise in physiological and pathological preclinical settings. Perrino C, Gargiulo G, Pironti G, Franzone A, Scudiero L, De Laurentis M, Magliulo F, Ilardi F, Carotenuto G, Schiattarella GG, et al. Am J Physiol Heart Circ Physiol 2011 300 6 1983 1989 10.1152/ajpheart.00784.2010 21490325
5. Inhibition of cellular ras prevents smooth muscle cell proliferation after vascular injury in vivo. Indolfi C, Avvedimento EV, Rapacciuolo A, Di Lorenzo E, Esposito G, Stabile E, Feliciello A, Mele E, Giuliano P, Condorelli G, et al. Nat Med 1995 1 6 541 545 10.1038/nm0695-541 7585120
6. Activation of cAMP-PKA signaling in vivo inhibits smooth muscle cell proliferation induced by vascular injury. Indolfi C, Avvedimento EV, Di Lorenzo E, Esposito G, Rapacciuolo A, Giuliano P, Grieco D, Cavuto L, Stingone AM, Ciullo I, et al. Nat Med 1997 3 7 775 779 10.1038/nm0797-775 9212106 (Pubitemid 27298723)
7. Mechanisms of restenosis after angioplasty and approach to therapy (Review). Indolfi C, Stabile E, Perrino C, Chiariello M, Int J Mol Med 1998 2 2 143 148 9855680
8. Inhibition of miR-92a increases endothelial proliferation and migration in vitro as well as reduces neointimal proliferation in vivo after vascular injury. Iaconetti C, Polimeni A, Sorrentino S, Sabatino J, Pironti G, Esposito G, Curcio A, Indolfi C, Basic Res Cardiol 2012 107 5 296 22890560
9. Effects of balloon injury on neointimal hyperplasia in streptozotocin-induced diabetes and in hyperinsulinemic nondiabetic pancreatic islet-transplanted rats. Indolfi C, Torella D, Cavuto L, Davalli AM, Coppola C, Esposito G, Carriero MV, Rapacciuolo A, Di Lorenzo E, Stabile E, et al. Circulation 2001 103 24 2980 2986 10.1161/01.CIR.103.24.2980 11413090 (Pubitemid 32578138)
10. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002 360 9326 7 22 12114036
11. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Knopp RH, d'Emden M, Smilde JG, Pocock SJ, Diabetes Care 2006 29 7 1478 1485 10.2337/dc05-2415 16801565 (Pubitemid 44127567)
12. Effects of hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin on smooth muscle cell proliferation in vitro and neointimal formation in vivo after vascular injury. Indolfi C, Cioppa A, Stabile E, Di Lorenzo E, Esposito G, Pisani A, Leccia A, Cavuto L, Stingone AM, Chieffo A, et al. J Am Coll Cardiol 2000 35 1 214 221 10.1016/S0735-1097(99)00526-4 10636283 (Pubitemid 30061283)
13. Hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin prevents cardiac hypertrophy induced by pressure overload and inhibits p21ras activation. Indolfi C, Di Lorenzo E, Perrino C, Stingone AM, Curcio A, Torella D, Cittadini A, Cardone L, Coppola C, Cavuto L, et al. Circulation 2002 106 16 2118 2124 10.1161/01.CIR.0000034047.70205.97 12379583 (Pubitemid 35192819)
14. Cardiac Side Effects of Chemotherapy: State of Art and Strategies for a Correct Management. Perrino C, Schiattarella GG, Magliulo F, Ilardi F, Carotenuto G, Gargiulo G, Serino F, Ferrone M, Scudiero F, Carbone A, et al. Curr Vasc Pharmacol 2012 22563720
15. Frequency of new coronary events in older persons with peripheral arterial disease and serum low-density lipoprotein cholesterol > or = 125 mg/dl treated with statins versus no lipid-lowering drug. Aronow WS, Ahn C, Am J Cardiol 2002 90 7 789 791 10.1016/S0002-9149(02)02616-4 12356403 (Pubitemid 35279409)
16. Statin therapy improves cardiovascular outcome of patients with peripheral artery disease. Schillinger M, Exner M, Mlekusch W, Amighi J, Sabeti S, Muellner M, Rumpold H, Wagner O, Minar E, Eur Heart J 2004 25 9 742 748 10.1016/j.ehj.2004.02.012 15120884 (Pubitemid 38647934)
17. Cardioprotective medication is associated with improved survival in patients with peripheral arterial disease. Feringa HH, van Waning VH, Bax JJ, Elhendy A, Boersma E, Schouten O, Galal W, Vidakovic RV, Tangelder MJ, Poldermans D, J Am Coll Cardiol 2006 47 6 1182 1187 10.1016/j.jacc.2005.09.074 16545650
18. Effect of pravastatin on progression and regression of coronary atherosclerosis and vessel wall changes in carotid and femoral arteries: a report from the Regression Growth Evaluation Statin Study. de Groot E, Jukema JW, van Boven AJ, Reiber JH, Zwinderman AH, Lie KI, Ackerstaff RA, Bruschke AV, Am J Cardiol 1995 76 9 40C 46C 10.1016/S0002-9149(99)80469-X 7572685
19. Drug therapy for improving walking distance in intermittent claudication: a systematic review and meta-analysis of robust randomised controlled studies. Momsen AH, Jensen MB, Norager CB, Madsen MR, Vestersgaard-Andersen T, Lindholt JS, Eur J Vasc Endovasc Surg 2009 38 4 463 474 10.1016/j.ejvs.2009.06.002 19586783
20. The rationale for using HMG-CoA reductase inhibitors ('statins') in peripheral arterial disease. Erez G, Leitersdorf E, Eur J Vasc Endovasc Surg 2007 33 2 192 201 10.1016/j.ejvs.2006.11.020 17185010 (Pubitemid 46090501)
21. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S). Pedersen TR, Kjekshus J, Pyorala K, Olsson AG, Cook TJ, Musliner TA, Tobert JA, Haghfelt T, Am J Cardiol 1998 81 3 333 335 10.1016/S0002-9149(97)00904-1 9468077 (Pubitemid 28099310)
22. Comparison of effects of statin use on mortality in patients with peripheral arterial disease with versus without elevated C-reactive protein and d-dimer levels. Vidula H, Tian L, Liu K, Criqui MH, Ferrucci L, Guralnik JM, Green D, Ridker P, McDermott MM, Am J Cardiol 2010 105 9 1348 1352 10.1016/j.amjcard.2009.12.054 20403491
23. Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease. Mondillo S, Ballo P, Barbati R, Guerrini F, Ammaturo T, Agricola E, Pastore M, Borrello F, Belcastro M, Picchi A, et al. Am J Med 2003 114 5 359 364 10.1016/S0002-9343(03)00010-X 12714124 (Pubitemid 36513683)
24. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Mohler ER 3rd, Hiatt WR, Creager MA, Circulation 2003 108 12 1481 1486 10.1161/01.CIR.0000090686.57897.F5 12952839 (Pubitemid 37176455)